English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
By Emon Reiser
Alimera Sciences on Tuesday named Elliot Maltz as chief financial officer.
Maltz succeeds Russell Skibsted in the role at Alimera. Skibsted held the role since January 2023.
The Atlanta-based pharmaceutical company said Maltz was most recently CFO at Orgenesis, a publicly traded biotechnology company centered on gene therapies. Before joining Orgenesis in September, Maltz was previously with Gelesis Holdings, a publicly traded commercial-stage company making weight-loss therapeutics.
The company said Skibsted’s departure is not due to any disagreement with management over operations or leadership.
Write to Emon Reiser at [email protected]
Read the full article here
